Updated 31 July 2026 · Clinically reviewed
The short answer: Retatrutide is not licensed in the UK. It cannot legally be prescribed, sold or supplied here for weight loss, and anything marketed as a “retatrutide pen” or “research peptide” is an illegal, unregulated product. Following the TRIUMPH-2 and TRIUMPH-3 results announced on 23 July 2026, Eli Lilly has confirmed it intends to file for approval in the first quarter of 2027 — which places realistic UK availability in 2028 at the earliest.
If you have searched for retatrutide UK in the last few weeks, it is almost certainly because of the headlines: a weekly injection producing weight loss figures that used to belong exclusively to bariatric surgery. Those headlines are real. The data behind them is now substantial, peer-scrutinised and, as of late July 2026, close to complete across the whole Phase 3 programme. What has not changed is the regulatory position. Retatrutide holds no marketing authorisation in the United Kingdom, the United States, or anywhere else in the world. No pharmacy can legally supply it. No prescriber can legally prescribe it.
That gap between enormous public interest and zero legal supply has created a thriving illegal market, and the Medicines and Healthcare products Regulatory Agency has spent the last nine months dismantling parts of it. This guide sets out exactly where retatrutide stands in the UK right now: what the trials actually found, when it might realistically reach British patients, why the products currently being sold online are dangerous, and what MHRA-licensed treatment you can access today if you are ready to start.
Retatrutide is an investigational once-weekly injection developed by Eli Lilly, known during development as LY3437943. It belongs to the same broad family of medicines as Wegovy and Mounjaro, but it works on more pathways than either of them.
The distinction matters, so it is worth being precise about it. Wegovy contains semaglutide, which activates a single receptor: GLP-1. Mounjaro contains tirzepatide, which activates two: GLP-1 and GIP. Retatrutide activates three — GLP-1, GIP and glucagon — which is why it is described as a triple hormone receptor agonist, or informally as a “triple G” drug.
The addition of glucagon receptor activity is the genuinely novel part. Glucagon is generally associated with raising blood sugar, which sounds counterintuitive in a diabetes and obesity drug. But glucagon also increases energy expenditure and drives fat mobilisation in the liver. Pairing it with GLP-1 and GIP activity appears to offset the glycaemic downside while adding a metabolic effect the dual agonists do not have. In the trials this has translated into two things: larger weight loss than any previously reported obesity drug, and unusually large reductions in liver fat.
How the receptor targets compare
Wegovy and the Wegovy Pill: GLP-1 only. Mounjaro: GLP-1 and GIP. Retatrutide: GLP-1, GIP and glucagon. More receptor targets has meant more weight loss in trials so far — but also, at the highest doses, more side effects and more discontinuations.
No. Retatrutide has not been granted a marketing authorisation by the MHRA, and it holds no approval from the FDA in the United States or the EMA in Europe either. It is an investigational medicine. Under the Human Medicines Regulations 2012, selling or supplying an unlicensed medicine for human use in the UK is a criminal offence, and that applies to retatrutide without exception.
The MHRA has stated its position plainly, warning that retatrutide “has not been approved for UK use” and that anything sold here claiming to contain it is likely illegal and potentially dangerous. There is no private prescription route, no specials route, no import route and no pharmacy route. The only lawful way any person in the UK receives retatrutide today is as a participant in an authorised clinical trial.
If you want to check for open studies, the NIHR Be Part of Research portal and ClinicalTrials.gov are the places to look. Be aware that most of the TRIUMPH programme has now finished recruiting, and trials involve randomisation — you may receive placebo.
A note on wording you will see online
Sellers use careful language to sidestep medicines law. Phrases like “research use only”, “not for human consumption”, “reference compound” and “lab grade” are not safety credentials. They are legal cover, and they sit alongside injection tutorials and before-and-after photos on the same pages.
The wording does not change what the product is or who is expected to inject it. It only changes who carries the risk, which is the buyer.
Retatrutide’s Phase 3 programme is called TRIUMPH, and it began in 2023. Twelve months ago there was no published Phase 3 data at all. As of the end of July 2026 there are four completed pivotal readouts plus a substudy, and the picture is no longer speculative.
TRIUMPH-4 was a 68-week trial in 445 adults with obesity or overweight who also had knee osteoarthritis, and no diabetes. Participants on the 12 mg dose lost an average of 28.7 per cent of body weight, alongside meaningful reductions in knee pain. It was the first signal that the Phase 2 results were going to hold up at scale, and it was also where the dysesthesia signal first appeared prominently.
TRIUMPH-1 is the trial that will underpin any obesity licence application. It randomised 2,339 adults with obesity or overweight plus at least one weight-related health condition, without diabetes, to retatrutide 4 mg, 9 mg, 12 mg or placebo, over an 80-week primary period. Average baseline weight was 112.7 kg, with an average BMI of 40. All three doses met the primary and key secondary endpoints.
The headline number from Lilly’s announcement of 21 May 2026 was 28.3 per cent average weight loss on 12 mg at 80 weeks — around 70 lbs. But two secondary findings are arguably more clinically interesting. First, 65.3 per cent of people on 12 mg finished the trial with a BMI under 30, meaning they no longer met the threshold for obesity. Second, weight loss had not plateaued at 80 weeks: in a pre-specified extension involving 532 participants with a baseline BMI of 35 or above, those continuing to 104 weeks reached an average of 30.3 per cent.
| TRIUMPH-1 at 80 weeks | 4 mg | 9 mg | 12 mg | Placebo |
|---|---|---|---|---|
| Average weight change | −19.0% | −25.9% | −28.3% | −2.2% |
| Average weight change in kg | −21.4 kg | −29.2 kg | −31.9 kg | −2.5 kg |
| Waist circumference change | −16.3 cm | −21.8 cm | −24.1 cm | −3.6 cm |
| Lost 25% or more of body weight | 27.8% | 52.9% | 62.5% | 2.2% |
| Lost 30% or more of body weight | 15.3% | 37.9% | 45.3% | 0.5% |
| Lost 35% or more of body weight | 5.9% | 20.8% | 27.2% | 0.3% |
| Stopped treatment due to side effects | 4.1% | 6.9% | 11.3% | 4.9% |
Figures shown are the efficacy estimand, which models the effect had all participants stayed on treatment. Under the treatment-regimen estimand, which reflects real-world adherence, the 12 mg figure at 80 weeks was 25.0 per cent. Both are legitimate; the second is the more conservative number and the one worth holding in mind.
One detail in TRIUMPH-1 has been under-reported and deserves attention, because it is the finding most likely to shape how retatrutide is actually used in practice. The 4 mg dose — reached after a single escalation step — produced 19.0 per cent average weight loss with a discontinuation rate lower than placebo. That is comparable to Wegovy’s efficacy with a tolerability profile that looks easier than the higher doses. If retatrutide is licensed, the low dose may well be where most patients sit.
This is the most recent development and the reason this guide has been rewritten. On 23 July 2026, Lilly reported positive topline results from two further pivotal trials, both at 80 weeks, and both meeting their primary endpoints.
TRIUMPH-2 studied 1,152 adults with type 2 diabetes and obesity or overweight, with an average baseline weight of 106.4 kg and average HbA1c of 7.7 per cent. The highest dose produced average weight loss of 20.8 per cent alongside an HbA1c reduction of 1.6 percentage points. The pattern of lower weight loss in a diabetic population than a non-diabetic one is consistent with everything seen with semaglutide and tirzepatide, and is expected rather than disappointing.
TRIUMPH-3 studied adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes. Average weight loss on the highest dose was 22.6 per cent. Cardiovascular risk markers moved substantially: triglycerides down 37.0 per cent, non-HDL cholesterol down 16.5 per cent, systolic blood pressure down 9.3 mmHg, waist circumference down 19.0 cm, and high-sensitivity C-reactive protein — an inflammation marker — down 51.2 per cent.
The caveat that matters in TRIUMPH-3
A secondary analysis found no statistically significant reduction in major cardiovascular events compared with placebo. Risk factors improved markedly; hard cardiovascular outcomes did not, in this trial. Whether retatrutide reduces heart attacks and strokes remains an open question, and answering it is the job of the separate dedicated cardiovascular outcomes trial, which is much larger and still running. Anyone presenting retatrutide as a proven cardioprotective drug is ahead of the evidence.
At the American Diabetes Association Scientific Sessions in June 2026, a sleep apnoea substudy nested within TRIUMPH-1 reported a 60.6 per cent reduction in the apnoea-hypopnoea index from a severe baseline of 58.6 events per hour. Separately, the TRANSCEND-T2D-1 trial — part of a distinct diabetes programme rather than TRIUMPH — reported an HbA1c reduction of up to 2.0 percentage points and 16.8 per cent weight loss at 40 weeks in 537 people with type 2 diabetes, and was published in The Lancet in June 2026.
| Trial | Population | Reported | Headline result |
|---|---|---|---|
| TRIUMPH-4 | Obesity with knee osteoarthritis | Dec 2025 | 28.7% weight loss at 68 weeks, reduced knee pain |
| TRANSCEND-T2D-1 | Type 2 diabetes | Mar/Jun 2026 | HbA1c down 2.0 points, 16.8% weight loss at 40 weeks |
| TRIUMPH-1 | Obesity or overweight, no diabetes | May 2026 | 28.3% at 80 weeks; 30.3% at 104 weeks in BMI 35+ extension |
| TRIUMPH-1 OSA substudy | Moderate to severe sleep apnoea | Jun 2026 | 60.6% reduction in apnoea-hypopnoea index |
| TRIUMPH-2 | Type 2 diabetes with obesity or overweight | Jul 2026 | 20.8% weight loss, HbA1c down 1.6 points at 80 weeks |
| TRIUMPH-3 | Severe obesity with established CVD | Jul 2026 | 22.6% weight loss; risk factors improved, CV events not significantly reduced |
| CV and renal outcomes trial | Large-scale outcomes study | Ongoing | Not yet reported |
| MASLD liver study | Fatty liver disease | Ongoing | Not yet reported |
@thecarepharmacyukStill snacking… just doing it smarter. You don’t have to cut everything out to see results. It’s about balance, better choices, and staying consistent. These are a few simple snack ideas to keep you on track 🩷 If you need any advice or guidance, your prescriber will be happy to help!♬ original sound – TheCarePharmacy
Until 23 July 2026 this question could only be answered with analyst guesswork. It can now be answered with a company statement. Alongside the TRIUMPH-2 and TRIUMPH-3 results, Lilly confirmed it intends to submit a Biologics Licence Application to the FDA in the first quarter of 2027, and that chemistry, manufacturing and controls work is being completed to support the filing.
Working forward from that, and applying the timescales UK regulators and NICE typically take, the realistic sequence looks like this. These are projections, not commitments, and drug timelines slip routinely.
| Stage | Expected timing | Confidence |
|---|---|---|
| FDA filing submitted | Q1 2027 | Stated by Lilly, 23 July 2026 |
| MHRA submission | 2027 | Likely, usually close behind or parallel to FDA |
| FDA decision | Late 2027 to 2028 | Projection based on standard 10 to 12 month review |
| MHRA marketing authorisation | 2028 | Projection; MHRA review typically 7 to 8 months |
| Private UK prescriptions possible | 2028 at the earliest | Follows authorisation, subject to supply |
| NICE appraisal and possible NHS access | 2029 onwards | Projection; NHS rollout of tirzepatide is phased over years |
There is one further variable specific to the UK. Even after tirzepatide received both MHRA authorisation and a positive NICE recommendation, NHS access has been rolled out in tightly prioritised phases starting with the highest BMI and greatest clinical need. There is no reason to expect retatrutide to be treated differently. For most people reading this, the private route will arrive years before the NHS route.
Lilly has also not yet announced a brand name for retatrutide, or any pricing. Any website quoting a UK retatrutide price today is quoting a number that does not exist.
Retatrutide is years away. The more useful question is what the trial evidence suggests you could achieve with a treatment you can legally access now. Enter your height and weight below to see your BMI and how the average results from the major trials would translate to your own starting weight.
The side effect profile is broadly what you would expect from an incretin-based medicine, dominated by gastrointestinal effects that are dose-related and most prominent during escalation. But there are two signals that are new to this class and worth understanding, because they are the ones a prescriber would be watching for.
| Side effect in TRIUMPH-1 | 4 mg | 9 mg | 12 mg | Placebo |
|---|---|---|---|---|
| Nausea | 28.6% | 38.4% | 42.4% | 14.8% |
| Diarrhoea | 25.2% | 34.1% | 32.0% | 13.5% |
| Constipation | 23.8% | 25.9% | 26.1% | 10.9% |
| Vomiting | 10.6% | 22.8% | 25.3% | 4.8% |
| Dysesthesia (altered skin sensation) | 5.1% | 12.3% | 12.5% | 0.9% |
| Urinary tract infection | 7.5% | 8.8% | 8.4% | 5.3% |
Dysesthesia is the signal that has drawn most clinical attention, because it does not feature in the semaglutide or tirzepatide profiles. It describes an abnormal skin sensation — tingling, prickling, burning or heightened sensitivity, often in the scalp or extremities. In TRIUMPH-1 it affected 12.5 per cent of the 12 mg group against 0.9 per cent on placebo. In the earlier TRIUMPH-4 trial the rate reported at 12 mg was considerably higher, up to 20.9 per cent. Cases were generally mild to moderate, most resolved while treatment continued, and most participants stayed on the drug — but it is a real, dose-related effect and its mechanism is not yet fully explained.
The urinary tract infection signal is smaller and its clinical significance less clear, but it is consistently above placebo across doses and will be scrutinised by regulators.
The dose-response relationship in the discontinuation data is the practical takeaway. On 4 mg, 4.1 per cent of participants stopped because of side effects — lower than the 4.9 per cent on placebo. On 12 mg, 11.3 per cent stopped. More weight loss came at a measurable tolerability cost, which is exactly the trade-off a prescriber and patient would need to discuss.
It also bears saying that the risks documented above are the risks of pharmaceutical-grade retatrutide, administered under close medical supervision, in a monitored trial, with dose escalation over months. None of those conditions apply to a vial bought online.
Because demand has outrun supply by several years, an illegal market has filled the gap. It takes two main forms: vials sold by peptide and research chemical websites, and counterfeit pre-filled pens produced in unlicensed facilities. Both are illegal to supply for human use in the UK, and both have been the subject of sustained MHRA enforcement.
| Date | Location | What the MHRA reported |
|---|---|---|
| Oct 2025 | Northampton | Over 2,000 unlicensed pens labelled as retatrutide or tirzepatide, tens of thousands of empty pens and raw chemicals. Described as the largest single seizure of trafficked weight loss medicines recorded globally. |
| Feb 2026 | Lincolnshire and Nottinghamshire | A second suspected manufacturing site disrupted. Almost 2,000 unapproved doses seized along with equipment, suspected ingredients and packaging. |
| May 2026 | Northamptonshire | A further operation recovering approximately 12,000 doses from a suspected large-scale production and supply site. |
There is an important nuance in how these seizures should be read. The public notices describe products labelled or suspected to contain retatrutide. They do not confirm laboratory results on the contents. So it would be wrong to claim every grey-market vial contains nothing — other manufacturers can synthesise a peptide with the retatrutide sequence.
But identifying the right molecule is only one test out of many, and it is the easiest one. A safe injection also requires the correct dose, an absence of process impurities and heavy metals, sterile manufacturing, control of bacterial endotoxin, validated cold-chain storage, and packaging that maintains stability. An unlicensed vial has demonstrated none of these. Injecting a non-sterile preparation subcutaneously is a direct route past every barrier your immune system has.
The consequences are not theoretical. In June 2026 Australia’s medicines regulator and Chief Medical Officer issued warnings about serious harm linked to unapproved peptide products, with reports including liver injury, severe allergic reactions and inflammation requiring medical treatment.
Eight signs you are looking at an illegal product
You can verify any UK pharmacy on the General Pharmaceutical Council register before you buy anything. The Care Pharmacy is registered with the GPhC under registration number 9010308.
@thecarepharmacyuk📍 Did you know we have a branch based in Bradford? Whether you need help with your prescriptions, healthcare advice, or access to pharmacy services, our Bradford team is here to support you. Pop in and say hello – we’re proud to be part of the local community 🩷♬ original sound – TheCarePharmacy
Many people have, and this is not a section written to shame anyone. If it applies to you, here is what to do.
Stop using it and keep the product and packaging. Do not throw it away. Photographs of the vial, label, batch details and the seller’s listing are useful clinical and regulatory information.
Speak to a healthcare professional and be straightforward about it. Tell them exactly what you took, how much, how often and for how long. They need to treat it as an unknown unlicensed injection rather than as confirmed retatrutide, because nobody can verify what was in it. Withholding the detail out of embarrassment makes their job harder and your care worse.
Report it through the Yellow Card scheme. Suspected reactions to unlicensed, falsified or uncertain products can and should be reported at yellowcard.mhra.gov.uk. Include the seller details, product name, claimed dose and photographs. This is how the MHRA maps the illegal supply chain.
Dispose of it properly. Ask a pharmacist. Do not put loose needles in household waste, and do not pass the product on to anyone else.
When to seek urgent help
Contact NHS 111 for urgent advice if you have vomiting or diarrhoea you cannot control, cannot keep fluids down, or have severe or persistent abdominal pain. Call 999 for difficulty breathing, facial or throat swelling, collapse or loss of consciousness.
This is the part that gets lost in retatrutide coverage. Waiting two or three years for an unlicensed drug means postponing treatment that is available now, regulated, and supported by years of safety data. The UK licensed landscape also changed significantly last month: on 11 June 2026 the MHRA approved oral semaglutide, the first weight loss tablet licensed in the UK, and it reached private prescription in July.
| Treatment | Active ingredient | How it is taken | Trial average | UK status |
|---|---|---|---|---|
| Mounjaro | Tirzepatide (GLP-1 and GIP) | Weekly injection | 22.5% | Licensed |
| Wegovy injection | Semaglutide (GLP-1) | Weekly injection | 14.9% | Licensed |
| Wegovy Pill | Oral semaglutide 25 mg (GLP-1) | Daily tablet | 13.6% | Licensed 11 June 2026 |
| Orlistat | Orlistat (fat absorption) | Capsule with meals | Around 5% | Licensed |
| Foundayo (orforglipron) | Orforglipron (GLP-1, small molecule) | Daily tablet | 11.1% | Not UK licensed. FDA approved April 2026 |
| Retatrutide | Retatrutide (GLP-1, GIP and glucagon) | Weekly injection | 28.3% | Not licensed anywhere |
Trial figures come from separate studies with different populations, durations and designs, so they should be read as indicative rather than as a like-for-like ranking. Mounjaro’s figure is from SURMOUNT-1 at 15 mg over 72 weeks; Wegovy injection from STEP 1 at 2.4 mg over 68 weeks; the Wegovy Pill from its oral semaglutide programme; retatrutide from TRIUMPH-1 at 12 mg over 80 weeks.
Of the licensed options, Mounjaro currently produces the largest average weight loss and is the closest available comparator to retatrutide, sharing two of its three receptor targets. If the appeal of retatrutide is the multi-receptor mechanism, tirzepatide is where that mechanism already exists in licensed, regulated form.
There is also a practical argument for starting now rather than waiting. Weight loss on these medicines is progressive over 12 to 18 months, and the TRIUMPH-1 extension data reinforced that longer treatment produces more loss. Two years spent on a licensed treatment will almost certainly deliver more than two years spent waiting for an unlicensed one.
Speak to a UK pharmacist, not a peptide website
Our GPhC-registered team assesses your eligibility, explains the realistic options, and supervises your treatment from the first dose onwards. Registration number 9010308.
Start your free consultation
Book supervised first injection
Retatrutide is the most effective obesity medicine yet reported in a Phase 3 trial, and after the July 2026 readouts its evidence base is close to complete. It is a genuine advance, and it is reasonable to be excited about it. But excitement about a future medicine is not a reason to take an unknown injection today.
The honest position for anyone searching retatrutide UK in July 2026 is this: it is not available, it will not be available for at least two years, and everything currently sold under its name is an unregulated product of unverifiable contents. Meanwhile, three MHRA-licensed treatments — including, since June, the UK’s first weight loss tablet — can be assessed and started within days, under the supervision of a registered pharmacist who is accountable for your care.
If retatrutide reaches the UK market, our clinical team will assess it and this page will be updated. Until then, the best thing you can do for your health is start something that works and is legal.
Medically reviewed by
Mohammed Ismail Lakhi (Mo) — MPharm, MRPharmS
Superintendent Pharmacist, The Care Pharmacy · GPhC registration 2072815
Pharmacy GPhC registration 9010308 · Reviewed 30 July 2026
This article is for general information and does not constitute medical advice or a recommendation to use any unlicensed medicine. Retatrutide is an investigational medicine and is not licensed for use in the United Kingdom. If you are considering weight loss treatment, speak to a registered UK pharmacist or your GP about MHRA-approved options. Suspected side effects from any medicine can be reported through the MHRA Yellow Card scheme.
Sources and further reading
Medically reviewed by
Superintendent Pharmacist
If you are researching weight loss options and trying to decide between gastric sleeve surgery and prescription weight loss medication, the decision is rarely as straightforward as it might first appear — and cost is only one of the factors worth considering carefully. Gastric sleeve surgery (sleeve gastrectomy) is a permanent surgical procedure that removes […]
Thinking of switching your weight loss treatment to The Care Pharmacy? Moving providers doesn’t mean restarting. This guide covers how switching works, what happens to your dose, what to bring, First Dose Video Supervision, transparent pricing for Mounjaro, Wegovy and Saxenda, and how to compare providers safely before you make the move.
Weight Loss · Emerging Treatments Cagrilintide: What It Is, How It Works, and Why It Could Change Weight Loss Medicine Everything you need to know about the next generation of obesity treatment — and what happens when it’s combined with a GLP-1. Updated June 2026 · Medically reviewed · 12 min read Important: This guide […]
Starting a new prescription medication always comes with questions. When that medication is as clinically potent as Mounjaro (tirzepatide), those questions tend to centre on one thing above all else: the side effects. What will they feel like? When will they start? And, perhaps most importantly, how long do Mounjaro side effects last? This guide […]
Starting Mounjaro is one thing. Getting the most from it is another. The clinical evidence for tirzepatide is compelling, but the patients who achieve the best outcomes are not simply those who inject once a week and hope for the best. They are the patients who understand how the medication works, adapt their habits to […]
Weight management on the NHS is available, and for many patients it remains an excellent option. But it is not accessible to everyone, and for those who do qualify, waiting times have become a significant barrier. As NHS weight management lists grow longer and the demand for prescription weight loss treatment continues to rise, a […]
